Safety and Immunogenicity Study of the Venezuelan Equine Encephalomyelitis Vaccine



Status:Enrolling by invitation
Conditions:Infectious Disease
Therapuetic Areas:Immunology / Infectious Diseases
Healthy:No
Age Range:18 - 65
Updated:8/17/2018
Start Date:September 2007
End Date:December 2019

Use our guide to learn which trials are right for you!

A Phase 2 Open-Label, Safety and Immunogenicity Study of a Single Dose of Venezuelan Equine Encephalomyelitis Vaccine, Live, Attenuated, Dried, TC-83, NDBR-102, as Primary Immunization in Healthy Adults At Risk for Exposure to Virulent Venezuelan Equine Encephalomyelitis Virus

This study is designed to determine safety of and immune response to Venezuelan Equine
Encephalomyelitis Vaccine, Live, Attenuated, Dried TC-83, NDBR-102 (TC-83).


Inclusion Criteria:

- At least 18 years old

- VEE PRNT80 < 1:10 before immunization.

- (females) Negative serum pregnancy test on same day before vaccination. Not planning
pregnancy for 3 months.

- Actively enrolled in the SIP

- At risk for exposure to virulent VEE virus (with up-to-date risk assessment).

- Up-to-date (within 1 year) physical examination/tests.

- Sign and date the approved informed consent.

- Willing to return for all follow-up visits.

- Agree to report adverse event (AE) up to 28 days after vaccination.

Exclusion Criteria:

- Over age of 65 years.

- Clinically significant abnormal lab results including evidence of Hepatitis C,
Hepatitis B carrier state, or elevated liver function tests.

- History of immunodeficiency or current treatment with immunosuppressive medication.

- (females) Currently breastfeeding.

- Confirmed human immunodeficiency virus (HIV) titer.

- Family history (first degree relative, but not elderly parent with late onset)
diabetes, personal history gestational diabetes, or confirmed elevated fasting serum
glucose (> 125 mg/dL).

- Serious allergic reaction to guinea pigs/guinea pig products.

- Any known allergies to components of the vaccine.

- A medical condition that in the judgment of the Principal Investigator (PI) would
impact subject safety (i.e-vaccination and or exposure to another alphavirus).

- Administration of any vaccine within 28 days of TC-83.

- Any unresolved AEs resulting from a previous immunization.
We found this trial at
1
site
1425 Porter Street
Fort Deterick, Maryland 21702
?
mi
from
Fort Deterick, MD
Click here to add this to my saved trials